The involvement of the transcription factor Yin Yang 1 in cancer development and progression

Cell Cycle

Volumn 8, Issue 9, 2009, Pages 1367-1372

  Castellano, Giancarlo ^a   Torrisi, Elena ^b   Ligresti, Giovanni ^b   Malaponte, Grazia ^b   Militello, Loredana ^b   Russo, Alessia E ^b   McCubrey, James A ^c   Canevari, Silvana ^a   Libra, Massimo ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cancer development; Drug resistance; Prognostic factor; Transcription factor; Tumor progression; Yin Yang 1

Indexed keywords

ANTINEOPLASTIC AGENT; FAS ANTIGEN; PROTEIN P53; TRANSCRIPTION FACTOR YY1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC ANALYSIS; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; MALE; MOUSE; MYELOID LEUKEMIA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; RECEPTOR UPREGULATION; REVIEW; SOMATIC CELL GENETICS; TRANSCRIPTION REGULATION; UPREGULATION; UTERINE CERVIX CANCER; VIRUS GENE;

EID: 65949094577     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.9.8314     Document Type: Review

References (54)

1. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9:730-756
2. Garban NJ, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of Fas promoter: a pivotal role for nitric oxide in the upregulation of Fas gene expression in human tumor cells. J immunol 2001; 167:75-81. (Pubitemid 32567763)
3. Sui G, Affar E, Shi Y, Brignone C, Wall NR, Yin P, et al. Yin Yang 1 is a negative regulator of p53. Cell 2004; 117:859-872
4. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 1991; 67:377-388 (Pubitemid 121001453)
5. Park K, Atchison ML. Isolation of a candidate repressor/activator, NF-E1 (YY-1, delta), that binds to the immunoglobulin kappa 3' enhancer and the immunoglobulin heavychain mu E1 site. Proc Natl Acad Sci USA 1991; 88:9804-9808 (Pubitemid 21915722)
6. Yao YL, Dupont BR, Ghosh S, Fang Y, Leach RJ, Seto E. Cloning, chromosomal localization and promoter analysis of the human transcription factor YY1. Nucleic Acids Res 1998; 26:3776-3783 (Pubitemid 28367985)
7. Shi Y, Lee JS, Galvin KM. Everything you have ever wanted to know about Yin-Yang 1. Biochim Biophys Acta 1997; 1332:49-66. (Pubitemid 27211616)
8. Hiromura M, Choi CH, Sabourin NA, Jones H, Bachvarov D, Usheva A. YY1 is regulated by O-linked N-acetylglucosaminylayion. J Biol Chem 2003; 278:14046-14052
9. Hyde-Deruyscher RP, Jennings E, Shenk T. DNA binding sites for the transcriptional activator/repressor YY1. Nucleic Acids Res 1995; 23:4457-4465
10. Uscheva A, Shenk T. TATA binding protein-indipendent initiation: YY1, TFIIB and RNA polymerase II direct basal transcription on supercoiled template DNA. Cell 1994; 76:1115-1121
11. Chang LS, Shi Y, Shenk T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J Virol 1989; 63:3479-3488 (Pubitemid 19181410)
12. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function and therapeutic implications in cancer biology. Oncogene 2006; 25:1125-1142 (Pubitemid 43297928)
13. Palko L, Bass HW, Beyrouthy MJ, Hurt MM. The Yin Yang-1 (YY1) protein undergoes a DNA-replication-associated switch in localization from the cytoplasm to the nucleus at the onset of S phase. J Cell Sci 2004; 117:465-476 (Pubitemid 38181208)
14. Blattner C. Regulation of p53: the next generation. Cell Cycle 2008; 7:3149-3153
15. Lane DP. p53 and human cancers. Br Med Bull 1994; 50:582-599
16. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fåhraeus R, Candeias MM. The p53 mRNA-Mdm2 interaction. Cell Cycle 2009; 8:31-34
17. Hongo F, Garban H, Huerta-Yepez S, Vega M, Jazirehi AR, Mizutani Y, et al. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosatio. Biochem Biophys Res Commun 2005; 336:692-701.
18. Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, et al. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 2005; 27:131-141
19. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005; 11:3686-3696
20. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, et al. Yin Yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 2009; 7:210-220
21. Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V, et al. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res 2008; 10:9.
22. Baritaki S, Sifakis S, Huerta-Yepez S, Neonakis IK, Soufla G, Bonavida B, et al. Overexpression of VEGF and TGFβ1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol 2007; 31:69-79.
23. De Nigris F, Botti C, de Chiara A, Rossiello R, Apice G, Fazioli F, et al. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer 2006; 42:2420-2424
24. Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P, et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol 2008; 8:112-122
25. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164:873-881
26. Sakhinia E, Glennie C, Hoyland JA, Menasce LP, Brady G, Miller C, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 2007; 109:3922-3928
27. Libra M, Castellano G, Baritaki S, Huerta-Yepez S, Ligresti G, Militello L, et al. Expression, role in transformation and prognostic significance of the transcription factor Yin Yang 1 (YY1) in non-Hodgkin's lymphoma: analyses in NHL tissues by experimental and bioinformatic approaches. Blood (ASH Annual Meeting Abstracts) 2008; 112:2827.
28. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005; 37:382-390 (Pubitemid 40490488)
29. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Eng J Med 2002; 346:1937-1947.
30. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419-2430
31. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22:2790-2799
32. Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34:791-808. (Pubitemid 28248487)
33. Liu H, Schmidt-Supprian M, Shi Y, Hobeika E, Barteneva N, Jumaa H, et al. Yin Yang 1 is a critical regulator of B-cell development. Genes & Dev 2007; 21:1179-1189 (Pubitemid 46789876)
34. Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res 2009; 15:851-857
35. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1:203-209
36. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63:3877-3882 (Pubitemid 36917897)
37. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001; 98:1176-1181
38. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 2006; 66:1354-1362 (Pubitemid 43259914)
39. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9:121-132
40. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007; 7:55.
41. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma and normal tissue examined by oligonucleotide arrays. Cancer Res 2001; 61:3124-3130 (Pubitemid 32691964)
42. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007; 121:2005-2012.
43. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13:1929-1939.
44. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45:938-947
45. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98:13790-13795
46. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005; 167:1763-1775
47. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006; 19:290-302.
48. Andersson A, Ritz C, Lindgren D, Edén P, Lassen C, Heldrup J, et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21:1198-1203
49. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8:782-798
50. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos D, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 upregulation. J Immunol 2007; 179:5441-5453
51. Baritaki S, Suzuki E, Umezawa K, Spandidos D, Berenson J, Daniels TR, et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008; 180:6199-6210
52. Baritaki S, Huerta-Yepez S, Toshiyuki S, Spandidos D, Bonavida B. Chemoterapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: upregulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007; 6:1387-1399 (Pubitemid 46712002)
53. Lee JY, Huerta-Yepez S, Vega M, Baritaki S, Spandidos DA, Bonavida B. The NO TRAIL to YES TRAIL in cancer therapy (review). Int J Oncol 2007; 31:685-691
54. Mijatovic S, Maksimovic-Ivanic D, Mojic M, Malaponte G, Libra M, Cardile V, et al. Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5- isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide 2008; 19:177-183